ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk

ACADIA Pharmaceuticals has returned about 19.3% over the past five years, yet recent valuation checks still flag the stock as screening cheap relative to its fundamentals, even after a strong one month move and mixed shorter term performance.

• Over a 5 year window, ACADIA Pharmaceuticals has delivered a 19.3% total return, which points to a moderate long term payoff rather than an outsized winner so far.
• The recent positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on Daybue can support expectations for future cash flows. At the same time, execution and regulatory follow through for the therapy remain key risks to how much value ultimately reaches shareholders.
• On Simply Wall St’s broader checks, ACADIA Pharmaceuticals looks cheap on several measures, with the stock assessed as undervalued in 5 of 6 valuation tests.

The issue now is whether ACADIA Pharmaceuticals’ recent gains already reflect the good news on Daybue, or if the current price still leaves a margin between the stock and what the valuation checks suggest it could be worth.

Find out why ACADIA Pharmaceuticals' 13.5% return over the last year is lagging behind its peers.

Is ACADIA Pharmaceuticals Still Cheap on Earnings?

The P/E ratio is a useful lens for ACADIA Pharmaceuticals because the company is now generating positive earnings that can be compared with peers. ACADIA Pharmaceuticals currently trades at about 11.7x earnings, which is below the broader Biotechs industry average of 17.3x and well under the peer group average of 41.2x. That puts the stock on a lower earnings multiple than many similar companies.

A fair P/E multiple for ACADIA Pharmaceuticals, based on its business profile and risk factors, is estimated at 19.0x. This is still comfortably above the current 11.7x level. Despite the recent lift from the positive CHMP opinion on Daybue in Rett syndrome, the stock’s P/E suggests the market is pricing ACADIA Pharmaceuticals at a discount to both its tailored fair multiple and sector benchmarks.

On this earnings-based measure, ACADIA Pharmaceuticals stock appears undervalued.

See what the numbers say about this price — find out in our valuation breakdown.

The ACADIA Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation work on ACADIA Pharmaceuticals leaves off. They spell out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price on the Community page. Each Narrative treats ACADIA Pharmaceuticals' implied fair value as a thesis about the business that can be revisited over time, rather than a one off snapshot.

On Simply Wall St, views on ACADIA Pharmaceuticals sit far apart, with one camp focused on underappreciated specialization and another on concentrated risk and policy pressure.

Bull case: 11% undervalued

"This creates a setup where the downside is well understood, but the upside depends on disciplined execution rather than speculative breakthroughs..."

Read the full Bull Case to see why ACADIA Pharmaceuticals could be undervalued

Bear case: 30% overvalued

"ACADIA remains heavily dependent on a narrow product portfolio dominated by NUPLAZID and DAYBUE, leaving the company acutely exposed to patent cliffs..."

Read the full Bear Case to see why ACADIA Pharmaceuticals could be overvalued

Do you think there's more to the story for ACADIA Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For ACADIA Pharmaceuticals, the current picture is that a low P/E multiple and broader valuation checks both lean toward the stock looking undervalued rather than stretched. The debate now is whether that discount reflects lingering concern over ACADIA Pharmaceuticals’ concentrated product risk, or whether the market is underestimating the earnings power if Daybue and the rest of the portfolio execute well. The key swing factor from here is whether the company can deliver on that execution without fresh setbacks, which would test whether today’s valuation gap represents a potential opportunity or a possible value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com